8-KOther EventsExhibits & Filings

JOHNSON & JOHNSON 8-K Report, Corporate Update (Sep 19, 2016)

Filed September 19, 2016For Securities:JNJ

Summary

Johnson & Johnson (JNJ) announced on September 16, 2016, a definitive agreement to acquire Abbott Medical Optics (AMO) for $4.325 billion in cash. AMO, a subsidiary of Abbott Laboratories, generated $1.1 billion in sales in 2015 and specializes in ophthalmic products across cataract surgery, laser refractive surgery, and consumer eye health. This strategic acquisition is expected to be immediately and modestly accretive to JNJ's adjusted earnings per share upon closing, which is anticipated in the first quarter of 2017. The transaction is contingent upon customary closing conditions, including antitrust clearance. This move signals JNJ's intent to bolster its presence in the growing eye health market, integrating AMO's portfolio into its Medical Devices segment, specifically within the Vision Care platform. Investors should note that the accretion to earnings is based on adjusted EPS, which excludes certain non-GAAP items. The company has also provided cautionary statements regarding forward-looking risks and uncertainties associated with the acquisition, including regulatory approvals, integration challenges, and market performance.

Key Highlights

  • 1JNJ to acquire Abbott Medical Optics (AMO) for $4.325 billion in cash.
  • 2AMO reported $1.1 billion in sales for 2015, indicating significant revenue contribution potential.
  • 3Acquisition includes diverse ophthalmic product lines: cataract surgery, laser refractive surgery, and consumer eye health.
  • 4Transaction is expected to close in Q1 2017, subject to antitrust clearance and other customary conditions.
  • 5The deal is anticipated to be immediately and modestly accretive to JNJ's adjusted earnings per share.
  • 6AMO's sales will be integrated into JNJ's Medical Devices segment, under the Vision Care platform.
  • 7Company has outlined potential risks and uncertainties associated with the acquisition and future integration.

Frequently Asked Questions

The acquisition of AMO is designed to significantly enhance Johnson & Johnson's position in the eye health market. AMO's established product portfolio in key areas like cataract surgery, laser refractive surgery, and consumer eye health, combined with its substantial sales ($1.1 billion in 2015), is expected to strengthen JNJ's Vision Care business within its Medical Devices segment and contribute to its overall growth.

The acquisition is expected to close in the first quarter of 2017. However, the completion is subject to standard closing conditions, most notably obtaining clearance from antitrust regulators and other customary conditions.

Johnson & Johnson stated that the transaction is expected to be immediately and modestly accretive to adjusted earnings per share following its expected close. It's important for investors to note that 'adjusted earnings per share' excludes intangible amortization expense and special items related to the transaction, so it's a non-GAAP measure.

Key risks include the possibility that the transaction may not be completed due to failure to obtain antitrust clearance or other closing conditions, the risk that the expected benefits and synergies may not be realized or may take longer than anticipated, and challenges related to the successful integration of AMO's products and employees into Johnson & Johnson's operations. Market and economic factors, competition, and regulatory changes are also cited as potential risks.